About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a publicly listed company based in Livermore (United States) founded in 1996. Monoclonal antibody therapeutics targeting Alzheimers disease are developed. Acumen Pharmaceuticals has raised $2.2 million across 4 funding rounds from investors including HHS, NeuroVentures and RA Capital. The company has 61 employees. Its Indian entity Acumen Pharmaceuticals Private Limited reported revenue of ₹7.07 Cr. Acumen Pharmaceuticals offers products and services including Sabirnetug (ACU193). Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its competitors include MacroGenics, Kodiak Sciences and BigHat; 3 of its 3 listed competitors have raised funding.
Company details
Acumen Pharmaceuticals was founded in 1996 and is headquartered in Livermore, United States. Monoclonal antibody therapeutics for Alzheimers disease are developed through a proprietary platform focused on fully humanized antibodies selective for abeta oligomers. These antibodies are also intended for use as diagnostic agents to measure abeta oligomer levels in cerebrospinal fluid, supporting efforts in the biotechnology sector.
- Headquarters Livermore, United States
- Employees 61
- Stage Public
- SectorsHealthcare
- Website acumenpharm.com
- Social LinkedIn X Facebook Instagram
- Legal Name Acumen Pharmaceuticals, Inc.
- Indian entity revenue₹7.07 Cr
FY 2025 · +7% YoY
- Indian entity net profit₹16 Lakh
FY 2025 · 2% margin
- Indian entity EBITDA₹56.3 Lakh
FY 2025 · 8% margin
- Total Equity Funding$2.2M (USD)
in 4 rounds
- Latest Funding Round$35.75M (USD), Post-IPO
Mar 2026
- InvestorsHHS
& 3 more
- Employee Count61
Associated legal entities of Acumen Pharmaceuticals
Acumen Pharmaceuticals operates through Acumen Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Private Limited CIN U24231TN2004PTC053713 | Active | 13 Jul 2004 | Madurai, Tamil Nadu | ₹7.1 Cr | 36 | 2 | View details |
Products & Services of Acumen Pharmaceuticals
Acumen Pharmaceuticals offers a comprehensive portfolio of products and services, including Sabirnetug (ACU193).
Targets toxic amyloid beta oligomers to treat early Alzheimer's disease.
Funding Insights of Acumen Pharmaceuticals
Acumen Pharmaceuticals has successfully raised a total of $2.2M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35.75 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.2M
- Total Rounds 4
- Last Round Post-IPO — $35.75M
- First Round $1.5M
(Aug 2006)
- Investors Count 4
All 4 funding rounds of Acumen Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $35.75M | Post-IPO | – | – | |
| Sep 2016 | $222,192 | Grant | – | – | |
| May 2013 | $700,000 | Private Equity Round | – | – | – |
| Aug 2006 | $1.5M | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in Acumen Pharmaceuticals
Acumen Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NeuroVentures and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| neuroventures.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| racap.com | ||||
| sandscapital.com |
Investor details for Acumen Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Acumen Pharmaceuticals Private Limited (Acumen Pharmaceuticals)
Acumen Pharmaceuticals Private Limited is the primary company behind Acumen Pharmaceuticals. The board of Acumen Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Nagaraju Shanmuga Sundaram, appointed in 2004.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nagaraju Shanmuga Sundaram DIN 01002313 | Managing Director | 13 Jul 2004 | 22 yrs 3 mo | Acumen Pharmaceuticals Private Limited |
| Nagaraju Vijayal DIN 01254561 | Director | 13 Jul 2004 | 22 yrs 3 mo | Acumen Pharmaceuticals Private Limited |
People of Acumen Pharmaceuticals
44 people are tracked at Acumen Pharmaceuticals (13 in leadership, 16 in board & advisors, 15 in team); the tracked headcount is 61.
| Name | Role | Group |
|---|---|---|
Kasey Spencer | Director, IT | Leadership |
Eric Siemers | Chief Medical Officer | Leadership |
Russell Barton | Chief Operating Officer | Leadership |
Daniel O’Connell | President & CEO | Leadership |
Matthew Zuga | CFO & Chief Business Officer | Leadership |
Derek Meisner | Chief Legal Officer | Leadership |
David Potter | Director, Data Management | Leadership |
Amber Dilley | Director, Quality Assurance | Leadership |
Katie Rink | Talent Acquisition & HR Business Partner | Leadership |
Janice Hitchcock | VP & Head of Regulatory Affairs | Leadership |
Alex Braun | VP, Head of Investor Relations | Leadership |
Kathleen Marcozzi Pierce | Director, Clinical Operations | Leadership |
Julie Bockenstette | EVP & Head of Human Resources | Leadership |
Steven DeKosky | Scientific Advisor | Board & advisors |
Grant Krafft | Scientific Advisor | Board & advisors |
Colin Masters | Scientific Advisor | Board & advisors |
Michael Weiner | Scientific Advisor | Board & advisors |
Cynthia Lemere | Scientific Advisor | Board & advisors |
Laura Stoppel | Director | Board & advisors |
Reisa Sperling | Scientific Advisor | Board & advisors |
24 more people are available in the full profile.
Complete people profiles for Acumen Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Acumen Pharmaceuticals
Acumen Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ABOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jul 2021
- Listed onNASDAQ: ABOS
- Listed entityAcumen Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS00509G2093
- Share price$1.81 (-10.15% on the day) · 2026-10-13
- Market capitalisation$131.3M
- EPS (diluted, trailing year)$-1.63
- Volume (last session)646,336
Financials of Acumen Pharmaceuticals
Figures of Acumen Pharmaceuticals Private Limited, the primary company behind Acumen Pharmaceuticals, for FY 2025. Revenue was ₹7.07 Cr (+7% year on year). Net profit was ₹16 Lakh (2% margin). EBITDA was ₹56.3 Lakh (8% margin). Revenue has grown at a compounded annual rate of +16% over three years and +11% over five years.
- ₹7.07 CrRevenue · FY 2025 · +7% YoY
- ₹16 LakhNet profit · 2% margin
- ₹56.3 LakhEBITDA · 8% margin
- ₹2 LakhPaid-up capital
- 36Employees (provident fund records)
- +16%Revenue CAGR, 3 years
- +11%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$121.3M | -$123.7M | |
| 2024 | -$102.3M | -$113.8M | |
| 2023 | -$52.4M | -$61.0M | |
| 2022 | -$42.9M | -$45.1M | |
| 2021 | -$100.6M | -$19.6M |
Balance sheet, profit and loss, cash flow and ratios of Acumen Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Acumen Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Acumen Pharmaceuticals
4 dated milestones of Acumen Pharmaceuticals across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Acumen Pharmaceuticals is founded.
- Funding First funding round of $1.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $35.8M.
Competitors of Acumen Pharmaceuticals
Acumen Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include MacroGenics, Kodiak Sciences and BigHat.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | Antibody therapies are developed through machine learning and synthetic biology. |
Detailed competitors of Acumen Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acumen Pharmaceuticals
The website of Acumen Pharmaceuticals (acumenpharm.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▲ 6.9% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Acumen Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acumen Pharmaceuticals
Complete news archive for Acumen Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acumen Pharmaceuticals
Acumen Pharmaceuticals was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Acumen Pharmaceuticals is headquartered in Livermore, United States. It is registered at Livermore, California, United States.
Acumen Pharmaceuticals is a funded company, having raised a total of $2.2M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $1.5M, raised on Aug 2006.
Acumen Pharmaceuticals has 61 employees.
The primary company behind Acumen Pharmaceuticals, Acumen Pharmaceuticals Private Limited, reported revenue of ₹7.07 Cr for FY 2025, up 7% year on year.
Acumen Pharmaceuticals was founded in 1996 and is headquartered in Livermore, United States. Monoclonal antibody therapeutics for Alzheimers disease are developed through a proprietary platform focused on fully humanized antibodies selective for abeta oligomers. These antibodies are also intended for use as diagnostic agents to measure abeta oligomer levels in cerebrospinal fluid, supporting efforts in the biotechnology sector.
Acumen Pharmaceuticals's top competitors include Kodiak Sciences, MacroGenics and BigHat.
Acumen Pharmaceuticals offers Sabirnetug (ACU193).
Yes, Acumen Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ABOS.
Acumen Pharmaceuticals has 4 investors. Key investors include HHS, NeuroVentures, RA Capital, and Sands Capital.
Acumen Pharmaceuticals operates through Acumen Pharmaceuticals Private Limited.
The legal entities of Acumen Pharmaceuticals currently have 2 directors, including Nagaraju Shanmuga Sundaram, Nagaraju Vijayal.